1 |
Bartel DP (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-33.
DOI
ScienceOn
|
2 |
Ashburner M, Ball CA, Blake JA, et al (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet, 25, 25-9.
DOI
ScienceOn
|
3 |
Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
DOI
ScienceOn
|
4 |
Benjamini YH, Y (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Statist Society Series B (Methodological), 57, 289-300.
|
5 |
Butt AJ, Caldon CE, McNeil CM, et al. (2008). Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol, 630, 189-205.
DOI
|
6 |
Carroll MC (2004). The complement system in regulation of adaptive immunity. Nat Immunol, 5, 981-6.
DOI
ScienceOn
|
7 |
Colomiere M, Ward AC, Riley C, et al (2009). Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer, 100, 134-44.
DOI
|
8 |
D'Andrilli G, Kumar C, Scambia G, Giordano A (2004). Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res, 10, 8132-41.
DOI
ScienceOn
|
9 |
Elledge SJ (1996). Cell cycle checkpoints: preventing an identity crisis. Science, 274, 1664-72.
DOI
|
10 |
Gautier L, Cope L, Bolstad BM, Irizarry RA (2004). affy-- analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 20, 307-15.
DOI
|
11 |
Holschneider CH, Berek JS (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol, 19, 3-10.
DOI
ScienceOn
|
12 |
Hsu SD, Lin FM, Wu WY, et al (2011). miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res, 39, D163-9.
DOI
|
13 |
Huang Q, Gumireddy K, Schrier M, et al (2008). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol, 10, 202-10.
DOI
|
14 |
Iorio MV, Visone R, Di Leva G, et al (2007). MicroRNA signatures in human ovarian cancer. Cancer Res, 67, 8699- 707.
DOI
ScienceOn
|
15 |
Lee RC, Feinbaum RL, Ambros V (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843-54.
DOI
ScienceOn
|
16 |
Irizarry RA, Hobbs B, Collin F, et al (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 4, 249-64.
DOI
ScienceOn
|
17 |
Johnson SM, Grosshans H, Shingara J, et al (2005). RAS is regulated by the let-7 microRNA family. Cell, 120, 635-47.
DOI
ScienceOn
|
18 |
Kusenda B, Mraz M, Mayer J, Pospisilova S (2006). MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 150, 205-15.
DOI
|
19 |
Lee YS, Dutta A (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev, 21, 1025-30.
DOI
|
20 |
Ma L, Teruya-Feldstein J, Weinberg RA (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449, 682-8.
DOI
|
21 |
Meng F, Henson R, Wehbe-Janek H, et al (2007). MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133, 647-58.
DOI
ScienceOn
|
22 |
Min H, Yoon S (2010). Got target? Computational methods for microRNA target prediction and their extension. Exp Mol Med, 42, 233-44.
DOI
|
23 |
Mok SC, Bonome T, Vathipadiekal V, et al (2009). A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell, 16, 521-32.
DOI
|
24 |
Nam EJ, Yoon H, Kim SW, et al. (2008). MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res, 14, 2690-95.
DOI
|
25 |
Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM (2005). Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett, 97, 171-9.
DOI
|
26 |
Murray KP, Mathure S, Kaul R, et al (2000). Expression of complement regulatory proteins-CD 35, CD 46, CD 55, and CD 59-in benign and malignant endometrial tissue. Gynecol Oncol, 76, 176-82.
DOI
|
27 |
Nam EJ, Kim YT (2008). Alteration of cell-cycle regulation in epithelial ovarian cancer. Int J Gynecol Cancer, 18, 1169-82.
DOI
|
28 |
Ono K, Tanaka T, Tsunoda T, et al (2000). Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res, 60, 5007-11.
|
29 |
Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA (2007). Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet, 3, e42.
DOI
|
30 |
Ricklin D, Lambris JD (2007). Complement-targeted therapeutics. Nat Biotechnol, 25, 1265-75.
DOI
|
31 |
Team RDC (2011). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.
|
32 |
van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA (2010). MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol, 42, 1282-90.
DOI
ScienceOn
|
33 |
Voorhoeve PM, le Sage C, Schrier M, et al (2006). A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell, 124, 1169-81.
DOI
ScienceOn
|
34 |
Zhang L, Huang J, Yang N, et al (2006). microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA, 103, 9136-41.
DOI
ScienceOn
|
35 |
Wang J, Zhou X, Zhu J, et al (2011). GO-function: deriving biologically relevant functions from statistically significant functions. Brief Bioinform.
|
36 |
Wightman B, Ha I, Ruvkun G (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75, 855-62.
DOI
ScienceOn
|